+10% over seven days: Hyloris share gains more than 7% after resumption of trading
The Belgian laboratory saw its listing suspended this morning during a visit by authorities to its headquarters. The share rebounds sharply higher in a slightly positive Paris market.
A visit to headquarters that briefly suspended trading
Hyloris share gains 7.06% to €4.40 during the session, compared to €4.11 at the previous close. The share thus exceeds its 20-day moving average (€4.18) and its 50-day moving average (€4.33), but remains 18.8% below its 200-day moving average (€5.42). The suspension of trading occurred this morning following the authorities' visit to headquarters. According to the statement, the matter concerns access to certain documents related to historical files, already discussed in previous exchanges with the FSMA. This 10% rebound over seven days is accompanied by the VIX rising 14.5% to 17.48, while the CAC 40 gains 0.31%.
A Japanese agreement and cash position secured until 2027
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The group signed at the end of September an agreement for Maxigesic IV in Japan. Its partner AFT Pharmaceuticals concluded with Mikasa Seiyaku the commercialization of this intravenous analgesic. Upon publication of the first half of 2026 results (September 23, 2026), the company specified that its chief executive officer provided a financial support letter of a maximum €2.5 million until September 30, 2027, which extends its cash visibility to the fourth quarter of 2027. The share is trading at €4.40, between its support level at €3.72 and its resistance level at €4.59.
Related
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 4,7 millions d'euros
Quarterly revenue: 4,7 millions d'euros
Net income: -1,9 millions d'euros
Guidance from the release
« After the reporting date, the Chief Executive Officer … issued a comfort letter … financial support up to a maximum amount of €2.5 million until 30 September 2027 » ; « this support extends the Company's cash runway into the fourth quarter of 2027 » ; « management has not identified any material uncertainties »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
